Compared with the anti-PD-1/CTLA-4 treatment alone, the anti-PD-1/CTLA-4 treatment plus TMDCs was significantly more potent in suppressing the tumor growth and inducing cytokines from tumor-infiltrating effector T cells and dendritic cells (Figures S6B, C). This evidence concerns the gene CTLA4 and neoplasm.